Sam Molina, PhD, is a protein scientist, cell biologist, and operational strategist whose career spans academic research, translational biotechnology, and the practical realities of regulated manufacturing environments. His work is unified by a central mission: helping organizations turn complex biological ideas into reproducible, scalable, and commercially deployable products. With deep expertise in protein expression, cell signaling, cellular systems behavior, assay development, and GMP‑aligned operations, Sam has become a trusted partner for companies navigating the increasingly intricate landscape of biologics, cell and gene therapy, and next‑generation research tools.

Sam’s scientific foundation is rooted in rigorous cell biology and protein biochemistry. His academic publications explore how cells process signals, regulate protein function, and respond to perturbations — insights that continue to shape his industry work. This grounding in cellular mechanisms gives him a unique perspective on how biological systems behave under real‑world constraints, and how upstream scientific decisions influence downstream manufacturability, quality, and regulatory readiness.

Over time, Sam expanded from bench‑level experimentation into the broader architecture of how therapies are made: starting materials, ancillary materials, workflow design, digital transformation, and the operational bottlenecks that determine whether a therapy can scale beyond a single lab. Through Molina BioConsulting, he now works with biotechnology companies, platform developers, and global suppliers to solve the practical challenges that slow development and limit patient access.

His work includes designing strategies for starting and ancillary materials in cell and gene therapy, advising on digital systems that replace manual, paper‑based processes, and supporting the development and validation of NAMs (New Approach Methodologies) for regulatory use. Sam is known for translating between disciplines — connecting cell biologists, protein engineers, regulatory teams, and manufacturing groups with a shared operational language. He brings clarity to complex systems, identifies hidden dependencies, and helps teams build the infrastructure required for scale.

Above all, Sam is driven by a commitment to improving patient access. He believes that scientific innovation only matters when it can be delivered reliably, affordably, and at scale — and he works with organizations to build the systems, materials, and operational foundations that make that possible.